Please login first

Synthesis, Characterization, Molecular docking and Structure-Activity Relationships of Novel 2-Arylidene- and 2-Aminomethylenethiazolo[3,2-a]pyrimidines as Prospective Acetylcholinesterase Inhibitors
Mohamed Y. Mahgoub * 1, 2 , Awatef M. Elmaghraby 2 , Abd-Elfttah A. Harb 2 , João L. Ferreira da Silva 1 , Gonçalo C. Justino 1 , M. Matilde Marques 1
1  a) Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal
2  b) Chemistry Department, Faculty of Science, South Valley University, Qena 83523, Egypt

Published: 01 November 2017 by MDPI AG in 3rd International Electronic Conference on Medicinal Chemistry session ECMC-3
10.3390/ecmc-3-04682
Abstract:

Acetylcholinesterase (AChE) is the enzyme that catalyzes the hydrolysis of the neurotransmitter acetylcholine (ACh) into acetic acid and choline, a crucial mechanism for regulation of neurotransmission at synapses in all nervous systems. According to the cholinergic hypothesis, depleted levels of ACh are associated with Alzheimer's disease. As part of a program aimed at preparing new bioactive heterocycles with kinase and AChE inhibition properties, we designed and synthesized a series of (Z)-2-arylidene- and 2-aminomethylene derivatives of thiazolo[3,2-a]pyrimidine by a convenient multicomponent method. The products were fully characterized by 1D- and 2D-NMR, high resolution ESI-MS/MS and single crystal X-ray diffraction analysis, which indicated a consistent Z configuration at the arylidene and amino methylene double bond. Additionally, molecular docking simulations of the series of 2-arylidene/aminomethylene-thiazolo[3,2-a]pyrimidine derivatives to human AChE (PDB ID: 4m0f, chain A) were conducted to investigate the binding mode of those compounds in comparison to Territrem B, used as positive control. The results indicate that some of the test compounds have binding energies to AChE that are comparable, or better, than the positive control, Territrem B. Biological activity studies are underway to assess the activities of the new compounds [1-4].

References:

  1. Francis, P.; Palmer, A.; Snape, M.; Wilcock, G. Neurol. Neurosurg. Psychiatry 1999, 66, 137-147.
  2. Zhi, H.; Chen, L.; Zhang, L.; Liu, S.-j.; Wan, D. C. C.; Lin, H.; Hu, C. Arkivoc 2008, 13, 266-277.
  3. Jin, C.H.; Jun, K.Y.; Lee, E.; Kim, S.; Kwon, Y.; Kim, K.; Na, Y. Med. Chem. 2014, 22, 4553-4565.
  4. Cheung, J.; Gary, E. N.; Shiomi, K.; Rosenberry, T. L. ACS Med. Chem. Lett. 2013, 4, 1091-1096.
Keywords: Thiazolopyrimidines; acetylcholinesterase; molecular docking; enzyme inhibition
Comments on this paper
Maria Emília Sousa
Very nice presentation
Very nice Project of medicinal Chemistry! congratulations!

Mohamed Mahgoub
Thanks prof. Sousa.

I invite you to see my keynote.

Best regards.



 
 
Top